Pfizer reported stronger-than-anticipated financial results for the second quarter, driven primarily by robust sales of its blood thinner, Eliquis, and increased revenue from recently acquired medications. The New York-based pharmaceutical company also outlined plans to accelerate its cost-saving measures, targeting an additional $2.5 billion in efficiencies.

The company now projects total net savings of $9.7 billion by 2029, a significant increase from previous estimates as Pfizer seeks to counterbalance declining income from its Covid-19 portfolio and sustain its overall growth trajectory. The expanded cost-cutting initiative aligns with Pfizer’s broader strategy to streamline operations and improve profitability amid a shifting pharmaceutical landscape.

Pfizer is aiming to reduce its reliance on legacy blockbuster drugs by emphasizing newer treatments with growth potential. A key part of this strategy involves leveraging its recent $10 billion acquisition of Metsera, which investors see as a critical move for Pfizer’s entry into the expanding obesity treatment market. The acquisition is expected to provide Pfizer with a foothold in a therapeutic area that has seen increasing demand worldwide.

The company’s optimism about future growth is tempered by ongoing challenges, including market competition and evolving healthcare dynamics post-pandemic. Nevertheless, Pfizer’s earnings report and updated cost-saving goals demonstrate its commitment to adapting its business model to meet these challenges while positioning itself for sustained long-term performance.